ANDA 215893, held by Apotex. Ponatinib Hydrochloride.
As of Nov 16, 2026, ANDA 215893 (Ponatinib Hydrochloride), held by Apotex, was first approved by FDA on Jul 14, 2023, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 14, 2023 | Original application | Approved |
| Ponatinib HydrochlorideEQ 15MG BASE · tablet;oral | Ponatinib Hydrochloride | Discontinued |
| Ponatinib HydrochlorideEQ 45MG BASE · tablet;oral | Ponatinib Hydrochloride | Discontinued |
| Nov 27, 2024 | Supplement 3Manufacturing | Tentative approval | None posted |
| Jul 14, 2023 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters